Global Onychomycosis Treatment Market Size is Estimated to Reach USD 4.51 Billion by 2030, Growing at a CAGR of 5.61%: Straits Research
29 févr. 2024 10h35 HE
|
Straits Research
New York, United States, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Onychomycosis is a fungal condition that affects the fingernails and toenails and can be painful, ugly, and persistent. Several types of...
Global Blood Culture Test Market Anticipated to Surge at a CAGR of 12.5% from 2023 to 2031 amidst Rising Bacterial Infections and Technological Advancements
19 déc. 2023 07h38 HE
|
Research and Markets
Dublin, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The "Global Blood Culture Test Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
Worldwide Blood Culture Test Industry to 2026 - Featuring Beckman Coulter, Biomerieux and Cepheid Among Others
18 août 2021 08h03 HE
|
Research and Markets
Dublin, Aug. 18, 2021 (GLOBE NEWSWIRE) -- The "Blood Culture Test Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Global Blood Culture Test Market Report 2020-2025: Outbreak of the COVID-19 Pandemic is Driving Market Growth
02 déc. 2020 04h58 HE
|
Research and Markets
Dublin, Dec. 02, 2020 (GLOBE NEWSWIRE) -- The "Blood Culture Test Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China
26 août 2020 05h40 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 26, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 07h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
29 juil. 2019 07h00 HE
|
Cidara Therapeutics, Inc.
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
03 avr. 2019 16h04 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics to Present at Two Upcoming Conferences
18 sept. 2017 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
06 oct. 2016 16h01 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has...